knowledge -WSS

knowledge

author：leisure time 2025-09-03 14:41:50 - browse：3836

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Maisha Meds is a PBM, but don't call it that

Wikipedia

WSS

Update the Apgar Score to remove skin color

FDA endorses new sterilization method for medical devices

EU regulator recommends expanding Mounjaro approval to obesity

Medicare bonuses could stop drug shortages under Senate plan

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

What causes osteoarthritis? Researchers study link to brain protein

Wikipedia

knowledge

hotspot

In Memoriam: Notable people who died in 2023

Humana cuts profit projections as Medicare Advantage costs soar

Psychedelics group wrestles with new pharma identity

EU regulator recommends expanding Mounjaro approval to obesity

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Humana cuts profit projections as Medicare Advantage costs soar

Hepatitis C has a cure — but many Americans still lack access to it

Cardiologists urge adding sexual orientation, gender identity to health records

Medical records are filled with copy

Francis Collins on trust in science and how Covid communications failed

hotspot

Elizabeth Holmes banned from government health programs

Dewpoint Therapeutics lays off staff after losing partnerships

A pediatrician calls for Congress to pass the child tax credit deal

What causes osteoarthritis? Researchers study link to brain protein

AI generated plenty of interest at JPM but not a lot of trust

HPV vaccine, cervical cancer study delivers historic results

Wikipedia

focus

focus

knowledge